NV
Novo Nordisk
NVO·NYSEBagsvaerd DKFounded 192364,000 employees
Large CappharmaPublicMetabolicRare DiseaseCardiology
Platform: GLP-1 Platform
Market Cap
$550B
All Drugs
14
Clinical Trials
23
Failed / Terminated
5
FDA Approved
0
Stock Price & Catalysts (NVO)
Loading NVO stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| NVO-1361 | NVO-1361 | Phase 3 | 2 | CD38 | GBMUrothelial Ca | ||
| NVO-7840 | NVO-7840 | Phase 2/3 | 1 | B7-H3 | HCC | ||
| Talainavolisib | NVO-7352 | Preclinical | 1 | KRASG12D | WMADHD | ||
| Ceviderotide | NVO-2828 | Preclinical | 2 | IL-13 | UCCRC | ||
| NVO-9630 | NVO-9630 | Phase 2 | 2 | CD3 | DMDFSGS | ||
| Terasacituzumab | NVO-5637 | NDA/BLA | 2 | IL-23 | HCCMeso | ||
| NVO-7872 | NVO-7872 | NDA/BLA | 1 | B7-H3 | PTSDNarcolepsy | ||
| Zorizanubrutinib | NVO-8395 | Phase 1 | 2 | BTK | Pompe | ||
| NVO-2974 | NVO-2974 | NDA/BLA | 1 | PARP | ETMCL | ||
| NVO-7877 | NVO-7877 | Preclinical | 2 | GPRC5D | Ovarian CaSCLC | ||
| Rimatenlimab | NVO-3433 | Phase 2/3 | 2 | SGLT2 | PBCPSP | ||
| NVO-9087 | NVO-9087 | Phase 1/2 | 1 | Tau | LNCF | ||
| NVO-6275 | NVO-6275 | Phase 1 | 2 | SMN2 | SLE | ||
| NVO-9615 | NVO-9615 | Phase 2/3 | 2 | PRMT5 | PVSCLC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (21)